RenovoRx, Inc. (RNXT)
| Market Cap | 72.66M +54.9% |
| Revenue (ttm) | 1.98M +198.5% |
| Net Income | -12.29M |
| EPS | -0.31 |
| Shares Out | 45.13M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 504,474 |
| Open | 1.730 |
| Previous Close | 1.720 |
| Day's Range | 1.630 - 1.730 |
| 52-Week Range | 0.701 - 2.590 |
| Beta | 1.12 |
| Analysts | Strong Buy |
| Price Target | 7.13 (+342.86%) |
| Earnings Date | Aug 12, 2026 |
About RNXT
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Financial Performance
In 2025, RenovoRx's revenue was $1.12 million, an increase of 2511.63% compared to the previous year's $43,000. Losses were -$11.17 million, 26.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for RNXT stock is "Strong Buy." The 12-month stock price target is $7.13, which is an increase of 342.86% from the latest price.
News
RenovoRx Transcript: H.C. Wainwright 28th Annual Global Investment Conference
RenovoCath's targeted drug delivery system is gaining rapid commercial traction, now in 21 centers with plans to exceed 35 by year-end. Interim phase III data show a six-month survival benefit and 65% reduction in toxicities, supporting raised revenue guidance and expansion into new cancer indications.
RenovoRx Slides: Investor presentation
RenovoRx has posted slides in relation to its latest quarterly earnings report, which was published on September 14, 2026.
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th
MOUNTAIN VIEW, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and com...
RenovoRx price target raised to $14.50 from $14 at Ascendiant
Ascendiant raised the firm’s price target on RenovoRx (RNXT) to $14.50 from $14 and keeps a Buy rating on the shares. The company’s Q2 results show strong momentum, the analyst…
RenovoRx publishes pharmacokinetic, pharmacodynamic data from TIGeR-PaC trial
RenovoRx (RNXT) announced the publication of pharmacokinetic and pharmacodynamic data from a sub-study of its ongoing Phase III TIGeR-PaC clinical trial in the journal Cancer Chemotherapy and Pharmaco...
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
PK/PD Data is from a Sub-Study in the Phase III TIGeR-PaC Clinical Trial The Study Shows Approximately 51% Tumor-Site Drug Extraction, Decreased Systemic Exposure, and Significant Correlation Between...
RenovoRx regains compliance with Nasdaq
RenovoRx (RNXT) announced that it has received written notification from Nasdaq confirming that the company has regained compliance with the minimum bid price requirement for continued listing on Nasd...
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
MOUNTAIN VIEW, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and comm...
RenovoRx receives notice of allowance for new RenovoCath U.S. patent
RenovoRx (RNXT) announced that the U.S. Patent and Trademark Office has issued a notice of allowance for the company’s patent application titled “Methods and Apparatuses for Delivery of Therapeutic Ma...
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
As Commercial and Clinical Programs Advance, RenovoRx Continues to Strengthen its Global Intellectual Property Portfolio with 20 Issued or Allowed Patents and 13 Pending Patents to Support the Commerc...
RenovoRx reports Q2 EPS (5c), consensus (8c)
Reports Q2 revenue $909,000, consensus $703,750. “In the second quarter of 2026, we delivered record revenue and executed on all three of the milestones we set for the business: revenue…
RenovoRx raises FY26 revenue view to $3.75M-$4.25M from $3M-$4M
Consensus $3.21M. The company said, “RenovoRx (RNXT) is raising and tightening the range of its full-year 2026 revenue guidance to a range of $3.75 million to $4.25 million, from its…
RenovoRx Transcript: Status update
TAMP is gaining traction as a less toxic, targeted therapy for locally advanced pancreatic cancer, with interim data showing reduced side effects and a trend toward improved survival. Commercial adoption is accelerating, supported by strong clinical and economic drivers, and the company is on track for break-even by late next year.
RenovoRx Earnings Call Transcript: Q2 2026
Record Q2 revenue and accelerated commercial center activation drove 115% year-over-year growth, with strong gross margins and improved operating loss. Guidance was raised for 2026, and expansion beyond pancreatic cancer was achieved, supported by robust clinical and commercial momentum.
RenovoRx Earnings release: Q2 2026
RenovoRx released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
RenovoRx Quarterly report: Q2 2026
RenovoRx has published its Q2 2026 quarterly earnings report on August 12, 2026.
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
Increases 2026 Annual Revenue Guidance to a Range of $3.75M to $4.25M First Treatment Delivered with RenovoCath ® in Patient with Sarcoma in Clinical Setting, Marking Expansion of Device to Other Sol...
RenovoRx completes enrollment in TIGeR-PaC trial
RenovoRx (RNXT) announced completion of enrollment in the company’s Phase III TIGeR-PaC trial in locally advanced pancreatic cancer. As of August 7, TIGeR-PaC trial investigators have been notified by...
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer
MOUNTAIN VIEW, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and comm...
RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors
MOUNTAIN VIEW, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and comm...
RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th
MOUNTAIN VIEW, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and comm...
RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET
MOUNTAIN VIEW, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and comm...
RenovoRx Transcript: IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026
The presentation highlighted a targeted, high-margin commercial strategy for a novel cancer therapy device, with rapid adoption in top centers, strong interim clinical data showing improved survival and reduced toxicity, and expansion into new indications. Break-even is expected next year, supported by robust cash reserves and a growing pipeline.
RenovoRx Slides: Investor presentation
RenovoRx has posted slides in relation to its latest quarterly earnings report, which was published on June 15, 2026.
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer
MOUNTAIN VIEW, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc.